Diabetes Treatment
60 articles on Diabetes Treatment, researched and written by the Shotlee Editorial Team from primary sources.
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.
8 min read
Fat Jabs Slash Alcohol-Related Hospitalisations by More Than a Quarter
Recent analysis indicates that GLP-1 weight loss medications significantly reduce the risk of alcohol-related hospital admissions by approximately 26 percent compared to other diabetes treatments.
8 min read
Doctors Warn a New GLP-1 Finding May Raise Your Risk of Smell Loss
Researchers analyzed nearly 877,000 patients and found a significant link between GLP-1 receptor agonists and sensory disturbances.
8 min read
New “Trojan Horse” Drug Supercharges Weight Loss in Early Trials
A new hybrid molecule designed by Helmholtz Munich researchers acts as a Trojan horse to deliver metabolic compounds directly into cells, showing superior weight loss in mice compared to standard treatments.
8 min read
China Adds Second GLP-1 Diabetes Drug to Essential Medicine List
China includes injectable semaglutide on its National Essential Drug List, improving access for diabetes patients while excluding obesity indications from the policy.
7 min read
Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising Claims in Legal Battle
Novo Nordisk has filed a lawsuit against Eli Lilly in the U.S. District Court for the District of New Jersey, alleging false advertising regarding GLP-1 weight loss medications.
7 min read
Ozempic Maker Novo Nordisk Sues Eli Lilly Over 'Materially Misleading' Ads
Novo Nordisk has filed a lawsuit against Eli Lilly, alleging deceptive advertising regarding weight-loss drugs. This legal battle highlights the intense competition between semaglutide and tirzepatide.
9 min read
Jim Cramer on Eli Lilly Amid Rival's GLP-1 Lawsuit
Jim Cramer weighs in on Eli Lilly's position in the GLP-1 market following a lawsuit from competitor Novo Nordisk, analyzing the situation for investors.
7 min read
Which GLP-1 Works Best? New Meta-Study Puts Medications Head-to-Head
A comprehensive meta-analysis from the University of Georgia compares three major GLP-1 medications. Discover which drug offers the highest weight loss efficacy and what the data means for patients.
8 min read
Ozempic Generics Recall: Why Cheap Semaglutide Copies Are Being Pulled
India's booming generic semaglutide market faces a credibility crisis as major manufacturers recall batches over quality concerns. Discover the implications for patient safety and treatment continuity.
9 min read
Semaglutide Supply Chain Halted: What Dr. Reddy's API Issue Means for You
Dr. Reddy's Laboratories has paused semaglutide shipments due to active ingredient quality concerns. Here is a deep dive into the impact on the GLP-1 market and patient care.
7 min read
Semaglutide's Essential Status in China: A Leap for Diabetes Care
China's decision to include semaglutide on its National Essential Drug List marks a significant step in improving diabetes management across the nation, promising greater accessibility for millions.
6 min read
Ozempic, Wegovy, Mounjaro: How Long Do GLP-1s Stay in Your System?
Curious about how long Ozempic, Wegovy, Mounjaro, or other GLP-1 medications stay in your system after your last dose? This comprehensive guide explores the science behind their elimination and what factors influence their duration.
7 min read
Semaglutide and Tirzepatide: The Reality of Stopping and Restarting
A groundbreaking analysis of diabetes medication patterns reveals that stopping isn't always permanent. Discover which drugs have the best retention rates and how insurance impacts access.
7 min read
Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation
The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.
7 min read
CagriSema Breakthrough: New Dual Therapy Delivers Major Weight Loss in Diabetes Trials
Explore the groundbreaking REIMAGINE trial results for CagriSema, a novel dual-agonist therapy showing superior glycemic control and weight loss in type 2 diabetes patients.
7 min read
Beyond the Headlines: Navigating Severe GLP-1 Side Effects
Actress Mayim Bialik's recent experience with severe gastrointestinal distress after starting a GLP-1 medication has brought a critical conversation to the forefront: the reality of significant side effects associated with these popular drugs. While GLP-1s offer profound benefits for many, understanding and managing potential adverse reactions is paramount.
7 min read
Beyond the Dose: Why Some GLP-1s Fall Short & What It Means
A groundbreaking Stanford study reveals a genetic reason why approximately 10% of individuals don't respond as expected to GLP-1 receptor agonists, impacting treatments for diabetes and weight loss.
7 min read
Beyond Ozempic: New Muscle-Burning Pill Reshaping Diabetes Care
A new experimental medication from Karolinska Institute targets muscle metabolism rather than appetite, offering a potential alternative to Ozempic and Wegovy with fewer side effects.
6 min read
GLP-1s and Alzheimer's: Hope, Hype, and the Science of Prevention
GLP-1 receptor agonists are showing promise for brain health by reducing inflammation, but experts caution that using these powerful medications solely for dementia prevention is premature, especially given mixed clinical trial results.
6 min read
Semaglutide and Pregnancy: Understanding New Risks and Weight Rebound
A recent national database study reveals significant obstetric risks associated with semaglutide exposure before and during pregnancy, highlighting the importance of the weight rebound effect.
7 min read
Beyond Weight Loss: Do GLP-1 Drugs Impact Mental Health?
New research is exploring the surprising potential of GLP-1 receptor agonists, known for their role in diabetes and weight management, to also influence mental well-being. This article delves into the latest findings and what they mean for patients.
7 min read
Ozempic, Mounjaro & Compounded GLP-1s: South Africa's Regulatory Crackdown
South Africa's regulatory bodies are taking decisive action against the booming market for compounded GLP-1 weight-loss drugs, including versions of Ozempic and Mounjaro. This crackdown highlights significant safety concerns and potential risks to public health.
8 min read
Ozempic Side Effects: AI Uncovers Hidden Symptoms on Reddit
Researchers at the University of Pennsylvania utilized artificial intelligence to analyze hundreds of thousands of Reddit posts, uncovering patient-reported side effects of GLP-1 medications that traditional clinical trials often overlook.
8 min read
Wegovy & Mounjaro Boom Fuels Peptide Production Surge for GLP-1 Drugs
The unprecedented demand for GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound is triggering a significant global expansion in peptide manufacturing. Learn how key players are investing billions to meet the surging need for these life-changing therapies.
7 min read
Oral Wegovy Approval: What the EU's Decision Means for Weight Loss
The European Medicines Agency has recommended approval for oral Wegovy, marking a significant shift in obesity treatment. Explore the implications for patients, efficacy data, and future access.
7 min read
Beyond Glucose: GLP-1 Therapies Reshape Metabolic Care
The GLP-1 receptor agonist market is experiencing explosive growth, transforming from a diabetes-focused treatment to a cornerstone of comprehensive metabolic care. Discover the key drivers, leading molecules like semaglutide and tirzepatide, and the future outlook.
10 min read
GLP-1 Weight Loss Drugs: Rising Costs & What It Means for Your Wallet
The soaring popularity and effectiveness of GLP-1 medications for weight loss are driving up healthcare costs, leading to potential increases in employee co-pays and changes in employer coverage strategies. This article explores the financial implications and what you need to know.
6 min read
Beyond the Scale: Are GLP-1 Drugs Depleting Vital Nutrients?
While GLP-1 agonists are revolutionizing weight management, emerging research suggests a potential downside: nutrient deficiencies. This article delves into what the latest studies reveal about these vital nutrient gaps and how to address them.
6 min read
Ozempic, Wegovy, Mounjaro: The GLP-1 Revolution Reshaping Health
The GLP-1 analogue market is experiencing unprecedented growth, transforming from diabetes treatments to comprehensive cardiometabolic solutions. Discover the key drivers, leading medications, and future innovations shaping this dynamic field.
9 min read
Wegovy and Eye Stroke Risk: What You Need to Know
A recent study has raised questions about a rare but serious eye condition linked to Wegovy. Learn more about ischemic optic neuropathy (ION) and what this research means for patients using GLP-1 medications.
7 min read
Beyond Ozempic: Why Vitamin Sales Soared After GLP-1's Rise
The launch of GLP-1 agonists like Ozempic and Wegovy has not only transformed weight management but also sparked an unexpected trend: a significant increase in vitamin supplement sales. This article delves into the potential reasons behind this phenomenon and what it signifies for individuals managing their health with these powerful medications.
8 min read
GLP-1 Medications and Supplement Needs: What You Should Know
As GLP-1 medications gain popularity for weight loss and diabetes management, understanding their impact on nutrient absorption is crucial. This article explores the link between these powerful drugs and the rising demand for supplements, offering insights from medical professionals and research.
6 min read
Eli Lilly 150 Years: AI, GLP-1 Advances & Future of Weight Loss
Eli Lilly celebrates 150 years with a focus on AI-driven manufacturing, new GLP-1 oral therapies, and expanded neuroscience research, signaling a major shift in pharmaceutical innovation.
8 min read
Amazon Stocks Oral Ozempic Pills: Same-Day Delivery & Pricing Guide
Amazon Pharmacy is expanding access to oral GLP-1 medications like Ozempic and Wegovy through kiosks and same-day delivery. Here is everything you need to know about pricing, logistics, and managing your treatment.
7 min read
CVS 2026 Outlook: Impact on GLP-1 Coverage, Insurance, and Care Access
CVS Health exceeded earnings expectations, but what does this mean for patients using GLP-1 medications like Ozempic or Wegovy? We break down the financial news and its real-world implications for your healthcare coverage.
8 min read
GLP-1 Drugs and Hair Loss: What the Latest Research Reveals
New research suggests a connection between GLP-1 medications and temporary hair loss. Discover what this means for users of drugs like Ozempic, Wegovy, and Mounjaro, and how to navigate this common side effect.
8 min read
FDA Proposes Curbs on Compounding Weight-Loss Drugs
The U.S. Food and Drug Administration (FDA) has proposed a significant change that could reshape the landscape of weight-loss drug accessibility. By suggesting the exclusion of key active ingredients from the list of drugs that outsourcing facilities can compound in bulk, the FDA aims to curb large-scale, unauthorized production of popular medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound).
7 min read
GLP-1 Drugs: Reshaping Canada's Food Landscape and Consumer Habits
What began as a treatment for diabetes has rapidly evolved into a powerful force reshaping consumer behavior and Canada's agri-food economy. GLP-1 drugs are no longer niche medical interventions; they are becoming mainstream, driving significant changes in how Canadians eat and shop.
6 min read
Oral Semaglutide Shows Promise for Pediatric Type 2 Diabetes
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
6 min read
Beyond 'Ozempic Teeth': Understanding and Managing 'Ozempic Breath'
The rise of GLP-1 medications like Ozempic and Mounjaro has brought about new conversations around their side effects, including the emerging concern of 'Ozempic breath.' This article delves into the causes, implications, and effective management strategies for this common issue.
7 min read
Eli Lilly's Oral GLP-1: A Strong Start Amidst Weight Loss Drug Hype
Eli Lilly's groundbreaking oral GLP-1, Foundayo, is demonstrating a promising launch, exceeding initial expectations and hinting at a significant expansion of the weight loss and diabetes management market. Discover the latest insights and what it means for patients and the industry.
7 min read
Orforglipron: The New Oral GLP-1 Challenger in Weight Loss
A new daily pill, Orforglipron, is emerging as a significant contender in the weight loss and diabetes management space, offering a potential oral alternative to injectable GLP-1 medications. This article delves into its mechanisms, trial results, and what it means for the future of treatment.
7 min read
Generic Semaglutide Approval in Canada: What It Means for Patients
Dr. Reddy's Laboratories has achieved a significant milestone by becoming the first company to receive market authorization from Health Canada for its generic semaglutide injection. This development promises to increase access to a crucial treatment option for Canadians.
6 min read
GLP-1 Medications: Miracle Drug, Wellness Trend, or Vanity?
GLP-1 medications have surged from diabetes treatment to mainstream wellness. This article examines their medical benefits, potential downsides, and the evolving societal perception of weight loss.
7 min read
Mounjaro (Tirzepatide) PBS Listing Fails: Impact on Australian Patients
Eli Lilly Australia has announced that Mounjaro (tirzepatide) will not be listed on the Pharmaceutical Benefits Scheme (PBS) for Type 2 Diabetes, citing unsustainable funding conditions. This decision highlights ongoing challenges in accessing modern GLP-1 and GIP therapies.
6 min read
Understanding the Mounjaro (Tirzepatide) PBS Standoff and What It Means for Patients
Eli Lilly has declined to list its highly effective GLP-1/GIP agonist, Mounjaro (tirzepatide), on the Pharmaceutical Benefits Scheme (PBS) in Australia, citing disagreements over pricing. This decision has significant implications for patients seeking access to this crucial medication for type 2 diabetes and increasingly, for weight management.
6 min read
Generic GLP-1s: Hope for Affordable Weight Loss & Diabetes Care?
As brand-name GLP-1 medications such as Ozempic and Wegovy become increasingly sought after for weight loss and diabetes management, many Canadians face significant cost barriers. The anticipation surrounding the approval of generic semaglutide offers a beacon of hope for improved accessibility and affordability. This article delves into the current landscape, patient stories, and expert insights on the journey towards more accessible peptide therapies.
7 min read
Generic Semaglutide Share Rises to 33% in 10 Days, Boosting Torrent, Dr. Redd...
The launch of generic Semaglutide in India has rapidly captured 33% market share within just 10 days, according to CLSA's channel checks, primarily benefiting Torrent Pharmaceuticals, Dr. Reddy's Laboratories, and Zydus Lifesciences. This surge has dented Eli Lilly's Mounjaro share from 61% to 56%. As generics make GLP-1 therapies more accessible, what does this mean for patients with type 2 diabetes and obesity?
5 min read
Tirzepatide Lowers Blood Sugar and Weight Faster in Type 2 Diabetes Study
A groundbreaking study reveals tirzepatide outperforms semaglutide and insulin degludec in speeding up blood sugar control and weight loss for type 2 diabetes patients. Participants on tirzepatide hit HbA1c targets below 7% in just eight weeks, compared to twelve weeks for alternatives. These faster results could boost long-term adherence and health outcomes.
4 min read
MSN Labs Launches Semabest: Generic Semaglutide in India
MSN Laboratories has launched Semabest, its affordable generic version of semaglutide, in the Indian market after CDSCO approval. Priced nearly 50% lower than the branded drug and available in pre-filled pens, it promises comparable efficacy in HbA1c reduction, glucose control, and weight loss. This move aims to address India's diabetes crisis affecting 90 million people.
5 min read
Arecor CEO on FY25 Highlights: AT278 & GLP-1 Progress
Arecor Therapeutics is advancing AT278, the only ultra-concentrated, ultra-rapid-acting insulin optimized for automated insulin delivery systems, addressing key limitations in current therapies. CEO Sarah Howell shares progress on a US Phase 2 trial partnership and oral GLP-1 platform developments. With a strengthened balance sheet, the company eyes major milestones in diabetes and cardiometabolic treatments.
4 min read
Retatrutide: Can This Shot Aid Weight Loss and Longevity?
Retatrutide, a promising new weight-loss injection, targets three hormone receptors to tackle obesity and diabetes head-on. Clinical trials demonstrate significant weight loss, and experts suggest it may support longevity goals too. Discover how this triple-action therapy stands out in metabolic health.
4 min read
Genetic Variants May Reduce GLP-1 Diabetes Drug Effectiveness
A new Stanford Medicine study uncovers why GLP-1 receptor agonists may not work as well for some Type 2 diabetes patients: certain genetic variants lead to GLP-1 resistance. Carried by about 10% of the population, these variants result in higher but less effective GLP-1 levels. This could guide faster, personalized treatment switches.
6 min read
Why Ozempic Doesn't Work for Everyone: Hidden Genetic Reason Found
Scientists have uncovered why Ozempic and similar GLP-1 drugs don't work for everyone: genetic variants in the PAM gene cause GLP-1 resistance in about 10% of people. Despite higher GLP-1 levels, these individuals show reduced drug effectiveness in lowering blood sugar. This breakthrough could pave the way for personalized treatment strategies.
5 min read
Hidden Reason Ozempic Fails for Some: GLP-1 Resistance Revealed
New research reveals a hidden genetic reason why Ozempic fails for some: GLP-1 resistance linked to PAM gene variants affecting 10% of the population. Despite higher GLP-1 levels, these individuals show reduced drug efficacy in lowering blood sugar. Discover the study's findings from humans, mice, and clinical trials.
7 min read
Genetic Mutations Linked to GLP-1 Drug Weight Loss and Side Effects
New studies uncover genetic variations in GLP1R and GIPR genes that predict better weight loss and higher side effect risks with GLP-1 drugs like Ozempic and Mounjaro. Cardiac protections from semaglutide appear separate from obesity reduction. A mouse study highlights noncoding DNA mutations' profound developmental impacts.
6 min read
Cheaper Generic Semaglutide in India: Experts Warn Against Quick-Fix Use
Cheaper generic semaglutide is transforming access to weight loss and diabetes treatment in India, priced at just Rs750 per weekly injection. However, experts caution against 'quick-fix' use without medical oversight, highlighting risks like 40% muscle loss from lean mass. Discover clinical evidence from STEP-1 and SELECT trials and why structured care is essential.
5 min read
GLP-1 Weight-Loss Drugs Face Bone Health Risks in Older Adults
Emerging research is raising questions about GLP-1 weight-loss drugs like Ozempic and Wegovy, showing a potential link to bone loss and fractures in older adults. A major study in the Journal of Clinical Endocrinology & Metabolism found higher fragility fracture risks among seniors on these medications. Experts stress monitoring and preventive steps to balance benefits with bone protection.
5 min read
Man Wanted for Stealing £12k Mounjaro After Court No-Show
A 27-year-old man from Wigan is being hunted by police after failing to appear in court on charges of stealing over £12,000 worth of Mounjaro weight loss injections from his workplace. The theft highlights the skyrocketing demand for this GLP-1 medication used for type 2 diabetes and appetite control. Understand the case details and what makes Mounjaro so sought after.
4 min read